| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H27N5O5.ClH |
| Molecular Weight | 441.909 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1C(=O)C=C(NCCN(CCO)CCCC2=CC=C(C=C2)[N+]([O-])=O)N(C)C1=O
InChI
InChIKey=YPVGGQKNWAKOPX-UHFFFAOYSA-N
InChI=1S/C19H27N5O5.ClH/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29;/h5-8,14,20,25H,3-4,9-13H2,1-2H3;1H
Nifekalant is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia. It has the brand name Shinbit. It is a nonselective K+ channel blocker without any β-blocking actions. Administration of nifekalant suppressed sustained ventricular tachyarrhythmias in acute coronary syndrome patients, and in cardiac arrest victims as well as during or after cardiac surgery. The major adverse effect of nifekalant is QT interval prolongation and occurrence of torsades de pointes which requires frequent monitoring of the QT interval during nifekalant infusion with adequate dose adjustment.
Originator
Approval Year
Cmax
AUC
T1/2
Doses
AEs
PubMed
Sample Use Guides
For acute coronary syndrome treatment the mean dose level of nifekalant was 0.19 ± 0.14 mg/kg body weight per hour;
For peri-operative Ventricular tachyarrhythmia treatment - intravenous administration of nifekalant in a dose of 0.3 mg/kg;
For cardiopulmonary resuscitation treatment - 0.15-0.3 mg/kg followed by intravenous infusion of 0.3-0.4 mg/kg per hour as antiarrhythmic therapy
Route of Administration:
Intravenous
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
